Introduction {#Sec1}
============

Infants undergoing congenital heart surgery (CHS) with cardiopulmonary bypass are at high risk of developing acute kidney injury (AKI) and fluid overload (FO). Infants receive proportionally more fluid than older patients relative to their size, increasing their risk of FO. Fluid overload, independent of AKI, is associated with increased length of stay and mortality in neonates undergoing heart surgery \[[@CR1]\]. Interestingly, FO in these patients is also associated with worse AKI, likely for multifactorial reasons \[[@CR1], [@CR2]\]. Some institutions routinely place peritoneal catheters to manage postoperative FO in neonates and young infants, using either passive peritoneal drainage, peritoneal dialysis, or both \[[@CR3]--[@CR8]\].

When used for dialysis after cardiac surgery, peritoneal catheters pose a low risk to the patient and have demonstrated benefits including better fluid management, quicker time to reach net-negative fluid balance, reduction in intra-abdominal hypertension, and even reduced serum markers of inflammation \[[@CR3]--[@CR6]\]. It is unclear whether the placement of passive peritoneal drains (PPDs) carry similar benefits, as small studies with dissimilar cohorts have yielded disparate results across different measures \[[@CR7]--[@CR9]\].

In our center, we place PPDs in select young infants (under 60 days) undergoing CHS who are deemed at greater risk of AKI and FO based on preoperative assessment or who are at high risk of postoperative diastolic dysfunction. Passive drainage begins in the immediate postoperative period in the Pediatric Intensive Care Unit, and drains are removed as the drain output downtrends and urine output has recovered. We hypothesized that prophylactic passive peritoneal drainage improves postoperative fluid output in these infants, specifically when controlling for the greater preoperative risk profile of the patients in whom they are placed. The aim of this retrospective study was to assess the effect of PPD placement on fluid management in these patients.

Material and Methods {#Sec2}
====================

This project was approved by the University of Wisconsin Institutional Review Board with patient consent waived. Patients for this retrospective cohort study were identified through the Society of Thoracic Surgeons (STS) database. STS data and retrospective chart review data were collected for all patients under 60 days of age who underwent congenital heart surgery (CHS) requiring cardiopulmonary bypass at the American Family Children's Hospital between January 2012 and September 2018. A diverse set of lesions were represented (Table [1](#Tab1){ref-type="table"}). Patients who required ECMO over their postoperative hospital course were excluded from analysis. Preoperative data included weight, creatinine, presence of chromosomal abnormality or syndrome, age at surgery, sex, history of low birth weight, and history of premature birth. Operative data included cardiopulmonary bypass time, aortic cross clamp time, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery (STAT) category, emergence from the operating room with open chest, and prophylactic insertion of a PPD.Table 1PPD and non-PPD cohorts had a broad array of diagnosesLesionPPD (*n* = 34)\
*n* (%)No PPD (*n* = 81)\
*n* (%)VSD1 (2.9)1 (1.2)Single ventricle11 (32.3)4 (4.9)AV canal defects0 (0)3 (3.7)Cor triatrium0 (0)3 (3.7)Tetralogy of fallot1 (2.9)9 (11.1)Coronary anomaly1 (2.9)1 (1.2)D-TGA6 (17.6)13 (16.0)D-TGA and VSD2 (5.9)2 (2.5)CoAo0 (0)2 (2.5)CoAo with other lesions1 (2.9)8 (9.9)Aortic Ah hyplasia3 (8.8)13 (16.0)IAA3 (8.8)0 (0)IAA and VSD1 (2.9)2 (2.5)Hemitruncus arteriosus0 (0)1 (1.2)Truncus arterius2 (5.9)2 (2.5)TAPVC2 (5.9)8 (9.9)Ebstein anoly0 (0)1 (1.2)DORV0 (0)5 (6.2)Other lesions0 (0)3 (3.7)*AV* Atrioventricular, *CoAo* coarctation of the aorta, *DILV* double inlet left ventricle, *DORV* double outlet right ventricle, *D-TGA* dextro-transposition of the great arteries, *HLHS* hypoplastic left heart syndrome, *IAA* interrupted aortic arch, *TAPVC* total anomalous pulmonary venous connection, *VSD* ventricular septal defect

Intraoperatively, modified ultrafiltration was used on all patients for this study. PPD placement occurred in the operating room following reversal of heparin. Patients were not randomized and were selected for PPD placement proactively by the surgical team out of concern for preoperative risk factors that may increase risk of postoperative fluid overload, such as higher STAT score, risk of diastolic dysfunction, and younger age. Single-cuff, 31 cm straight Tenckhoff peritoneal catheters (Covidien, Minneapolis, MN) were placed in the epigastrium and directed to the left pericolic gutter under direct visualization. The peritoneum was closed separately from the drain entrance site. To reduce the possibility of incisional hernia, a 5--0 polypropylene stay suture was pre-placed through the abdominal wall at the stab incision site. The collection bag was connected and kept on the bed. Drains were removed while patients were still intubated and as urine output increased, although there was no absolute volume threshold or protocol for drain removal. The surgical team and approaches remained the same throughout the timeframe examined in this study, and there was no era differentiation. Postoperative care pathways and institutional practices for the management of postoperative CHS patients did not change through the course of the study. Notably, dialysate was not used for these patients; our institution rarely uses peritoneal dialysis postoperatively but has in the case of significant AKI with hyperkalemia, which was not experienced by patients in this cohort.

Postoperative data analyzed included daily weight (in kilograms), urine output (mL/kg/24 h), PPD output (mL/kg/24 h), total fluid output (mL/kg/24 h), and total fluid intake (mL/kg/24 h) for 5 days postoperatively or two days after removal of the PPD, whichever came last. Total fluid output included chest and mediastinal drain output. The incidence of AKI within the first ten postoperative days, as determined by the creatinine component of the neonatal modified Kidney Disease: Improving Global Outcomes (KDIGO) criteria, was determined \[[@CR10], [@CR11]\]. KDIGO urine output criteria was not utilized given that it was anticipated that PPD placement would likely be associated with lower urine output. First day with net negative fluid balance was recorded. Daily furosemide dosing per preoperative kilogram weight was tracked over POD 1--5. Chlorothiazide, spironolactone, bumetanide, and hydrochlorothiazide administration were also tracked.

We examined several variables to detect physiologic consequences of postoperative fluid overload, including time to chest closure for those with delayed sternal closure, duration of postoperative invasive ventilation (hours), immediate postoperative dynamic respiratory compliance, and daily dynamic respiratory compliance at 7 am. The dynamic respiratory compliance examined was a single value within 60 min of 7 am and the closest value to that time. Additionally, maximum daily vasoactive-inotropic score was calculated through POD 3 \[[@CR12]\]. Death within 30 days of surgery, death prior to discharge, STS surgical mortality, and hospital length of stay were noted. Of note, our institution uses an adjustable care model in which the patient stays in the same ICU room until discharge, preventing measurement of ICU length of stay. Total daily diuretic administration was calculated through POD 5.

Statistical methods {#Sec3}
-------------------

All analyses were conducted using *R* software version 3.6.0 (Vienna, Austria). For univariate analysis, continuous variables were reported as mean, standard deviation, and *t* test *p* value. Preoperative and operative input data were compared between PPD and non-PPD groups, and multivariable analysis was completed for inputs with between-group p values of ≤ 0.1. Ultimately, models utilized each of the following predictors: STAT category, bypass time, age at surgery, weight at surgery, and presence of delayed chest closure (Table [2](#Tab2){ref-type="table"}).Table 2Preoperative and operative patient demographics demonstrate that the PPD patient cohort has a higher risk profile with significant differences in STAT category, bypass time, age at surgery, and prevalence of delayed chest closurePPD (*n* = 34)\
*n* (SD or % sample)No PPD (*n* = 81)\
*n* (SD or % sample)*P*-valueFemale sex12 (35%)34 (42%)0.539Premature birth (\< 36 weeks)4 (12%)18 (22%)0.298Identified syndrome or chromosomal disorder8 (24%)19 (24%)1Low birth weight (\< 2 kg)2 (6%)8 (10%)0.721Presence of delayed chest closure25 (74%)18 (22%) \< 0.001Weight at surgery (kg)3.20 (0.53)3.42 (0.77)0.09Preoperative creatinine0.50 (0.17)0.44 (0.14)0.114Age at surgery (days)10.56 (12.64)16.49 (15.85)0.037Bypass time (minutes)185.62 (46.23)152.74 (45.27)0.001Cross clamp time (minutes)82.62 (29.91)72.59 (34.22)0.141STAT category 11 (3%)2 (2%) \< 0.001STAT category 22 (6%)13 (16%)STAT category 36 (18%)15 (19%)STAT category 412 (35%)47 (58%)STAT category 513 (38%)4 (5%)*OR* Operating room, *PPD* passive peritoneal drain, *SD* standard deviation, *STAT* society of thoracic surgeons-European Association for Cardio-Thoracic Surgery

Multivariable outcomes of interest included fluid intake (mL/kd), urine output (mL/kg), total fluid output (mL/kg), and furosemide administration (mg/kg), each cumulatively over POD 1--5. Other multivariable outcomes of interest included POD 0 fluid intake (mL/kg), daily percent increase above preoperative weight for POD 1--5, number of postoperative days to first day net negative, incidence of KDIGO Stage 1 and 2 AKI by creatinine criteria, and peak daily vasoactive-inotropic score (VIS) over POD 0--3. Postoperative hours on ventilator, postoperative days to delayed chest closure in the presence of an open chest, postoperative hospital length of stay, dynamic respiratory compliance (mL/cmH2O) on postoperative arrival to the pediatric ICU, and dynamic respiratory compliance (mL/cmH2O) at 7am POD1-2 were also included in multivariable analysis.

In multivariable modelling, STAT category was treated as a categorical predicator with a baseline of 1. For continuous outcomes, a multivariable linear regression model was fit to adjust for the above predictors. Results were reported as effect estimate, 95% confidence interval for the effect estimate, and the *p* value testing whether the effect estimate is significantly different from 0, with a significance threshold set a priori as *p* ≤ 0.05. All outcomes measured were continuous except for incidence of KGIDO creatinine stage 1 AKI and incidence of KDIGO creatinine stage 2 AKI, which were categorical. For these categorical outcomes, a multivariable logistic regression model was fit adjusting for the aforementioned predictors. Results were reported with an odds ratio, 95% confidence for the odds ratio, and *p* value testing whether the odds ratio is significantly different from 1, with a significance threshold set a priori as *p* ≤ 0.05.

Results {#Sec4}
=======

Between January 2012 and September 2018, 124 CHS cases requiring bypass were performed in children under 60 days. Of these patients, 9 were excluded from analysis for requiring postoperative ECMO (4 PPD, 5 no PPD), leaving for analysis 34 patients who received prophylactic PPDs and 81 who did not (Fig. [1](#Fig1){ref-type="fig"}). Amongst analyzed patients, there were no deaths prior to discharge or within 30 postoperative days, for an STS operative mortality of 0. PPDs were in place for a mean of 4.7 (st. dev 1.8) postoperative days. PPD placement was successful in all intended patients, and all PPDs worked appropriately up to removal. No direct complications of PPD placement were observed.Fig. 1Patient cohorts and exclusions. *CPB* cardiopulmonary bypass, *CHS* congenital heart surgery, *ECMO* extracorporeal membrane oxygenation, *PPD* passive peritoneal drain

Demographics and Operative Data {#Sec5}
-------------------------------

No significant differences were identified between the PPD and non-PPD groups by sex, weight at surgery, preoperative creatinine, presence of premature birth (\< 36 week gestation), presence of identified syndrome/chromosome abnormality, presence of low birth weight (\< 2000 g), and cross clamp time (Table [2](#Tab2){ref-type="table"}). Significantly, PPD patients were younger at surgery, had longer bypass times, and were more likely to have delayed chest closure than non-PPD patients. The STAT-category distribution also significantly differed between groups, with PPD patients undergoing higher STAT-category procedures (Table [2](#Tab2){ref-type="table"}). Inputs with *p* values ≤ 0.1 were included in multivariable analysis and include STAT category, bypass time, age at surgery, weight at surgery, and presence delayed chest closure (Table [2](#Tab2){ref-type="table"}). Mean gestational age at birth was 38.3 (st dev 2.3) weeks for the PPD patients and 38.1 (st dev 2.6) weeks for the non-PPD patients.

Vasoactive-Inotropic Scores {#Sec6}
---------------------------

PPD patients had significantly higher peak vasoactive-inotropic scores (VIS) on POD 0 in univariate analysis, but this was not seen in multivariable analysis. Peak daily VIS remained higher over each of POD 1--3 in both univariate and multivariable analysis (Table [3](#Tab3){ref-type="table"}).Table 3POD 1--3 peak daily VIS and the incidence of KDIGO AKI are significantly higher for PPD patients in univariate analysis, but AKI rates do not reach statistical significance in multivariable analysisUnivariate analysisMultivariable analysisPPD (*n* = 34)\
Mean (SD)\
or incidence (%)No PPD (*n* = 81)\
Mean (SD)\
or Incidence (%)*P*-valueEffect estimates\
(OR if binary)95% CI*P*-valuePeak daily vasoactive-inotropic score POD 012.6 (5.3)9.0 (5.1)0.0021.32− 1.04, 3.680.278 POD 115.8 (9.8)9.1 (5.1) \< 0.0014.501.22, 7.780.009 POD 210.8 (5.7)6.8 (3.6) \< 0.0012.710.85, 4.570.005 POD 39.3 (3.8)5.7 (2.9) \< 0.0012.310.89, 3.740.002Incidence of KDIGO creatinine Stage 1 AKI58.8%30.9%0.007OR = 2.00.7, 5.70.199Incidence of KDIGO creatinine Stage 2 AKI23.5%4.9%0.006OR = 4.00.9, 18.20.071*AKI* Acute kidney injury, *CI* confidence interval, *KDIGO* kidney disease: improving global outcomes, *OR* odds ratio, *POD* postoperative day, *PPD* passive peritoneal drain, *SD* standard deviation

AKI by KDIGO Creatinine Criteria {#Sec7}
--------------------------------

Patients with a PPD had a significantly higher incidence of KDIGO Stage 1 AKI and KDIGO Stage 2 AKI by creatinine criteria in univariate analysis, although differences did not reach statistical significance after multivariable analysis (Table [3](#Tab3){ref-type="table"}).

Postoperative Hospital Length of Stay and Time to Chest Closure {#Sec8}
---------------------------------------------------------------

In univariate and multivariable analysis, there were no significant differences between PPD and non-PPD patients in total postoperative hospital length of stay (Table [4](#Tab4){ref-type="table"}). All patients who emerged from the OR with an open chest later underwent chest closure. Of PPD patients that came from the OR with open chest (25 of 34), chest closure occurred at an average of 3.9 (st dev 0.9) postoperative days, while the average for non-PPD patients with delayed chest closure (18 of 81) was also 3.9 (st dev 0.9) postoperative days (*p* = 0.824). Multivariable modeling for those with delayed chest closure demonstrated no significant difference between PPD and non-PPD patients in time to closure, with PPD presence accounting for a − 0.3 day difference in time to closure (95% CI \[− 0.93, 0.32\], *p* = 0.35).Table 4Multivariable analysis demonstrates no significant difference in measured dynamic respiratory compliance, postoperative hours on the ventilator, or postoperative hospital length of stayUnivariate analysisMultivariable analysisPPD\
(total *n* = 34)\
Mean (SD)No PPD\
(total *n* = 81)\
Mean (SD)*P*-valueEffect estimate95% CI*P*-valueDynamic respiratory compliance (mL/cmH~2~O) Post-op arrival to PICU1.4 (0.46)1.58 (0.60)0.097− 0.11− 0.36, 0.150.414 POD 1 7 am1.70 (0.57)1.75 (0.81)(9 omitted)0.6960.02− 0.26, 0.300.875 POD 2 7 am1.77 (1.01)1.73 (0.69)(18 omitted)0.8230.13− 0.26, 0.520.526Post-op hours on ventilator141 (69)88 (57) \< 0.0014.32− 22.31, 30.960.751Post-op hospital length of stay25.0 (15.5)19.0 (11.6)0.052− 2.91− 8.29, 2.460.291*CI* Confidence interval, *OR* odds ratio, *PICU* pediatric intensive care unit, *POD* postoperative day, *PPD* passive peritoneal drain, *SD* standard deviation

Dynamic Respiratory Compliance and Postoperative Ventilator Hours {#Sec9}
-----------------------------------------------------------------

In both the univariate and multivariable analyses, there was no significant difference between PPD and non-PPD patients in dynamic respiratory compliance at any time point examined (Table [4](#Tab4){ref-type="table"}). In univariate analysis, postoperative hours of intubation were significantly higher in PPD patients, but a significant difference was not found after multivariable adjustment (Table [4](#Tab4){ref-type="table"}).

Postoperative Daily Weights and First Day Net Negative Fluid Balance {#Sec10}
--------------------------------------------------------------------

In univariate and multivariable analysis, there was no significant difference between PPD and non-PPD groups in time to first day with net negative fluid balance (Table [5](#Tab5){ref-type="table"}). PPD patients had significantly higher percent weight increase on each of POD 1--5 in univariate analysis, but differences were not significant after multivariable adjustment (Table [5](#Tab5){ref-type="table"}).Table 5PPD use demonstrates no improvement in time to net negative fluid balance but is associated with increased total fluid output over multivariable analysis of POD 1--5 despite similar fluid intake and reduced furosemide exposureUnivariate analysisMultivariable analysisPPD\
(*n* = 34)\
Mean (SD)No PPD\
(*n* = 81)\
Mean (SD)*P*-valueEffect estimate95% CI*P*-valueIntake (mL/kg) POD 0385 (146)327 (311)0.179− 90.8− 225.11, 43.580.189 POD 1--5578 (107)566 (99)0.57140.66− 7.08, 88.410.099Urine output (mL/kg) POD 1--5396 (120)470 (101)0.003− 61.53− 110.31, − 12.740.015PPD output (mL/kg) POD 1--5107 (82)n/an/an/an/an/aTotal output (mL/kg) POD 1--5647 (128)606 (98)0.10848.792.19, 95.390.043Furosemide (mg/kg) POD 1--56.63 (2.96)9.36 (4.28) \< 0.001− 3.41− 5.14, − 1.69 \< 0.001Percent increase above pre-operative weight POD 121 (10)14 (11)0.0170.02− 0.05, 0.090.496 POD 221 (11)15 (10)0.0220.03− 0.02, 0.090.261 POD 319 (12)12 (11)0.0200.03− 0.03, 0.090.383 POD 413 (11)8 (10)0.0260.02− 0.03, 0.070.461 POD 511 (11)5 (10)0.0110.03− 0.02, 0.080.279Number of post-op days to first day net negative2.1 (1.0)2.0 (0.8)0.4900.11− 0.28, 0.500.581*CI* Confidence interval, *POD* postoperative day, *PPD* passive peritoneal drain, *SD* standard deviation

Fluid Intake and Outputs {#Sec11}
------------------------

In univariate and multivariable analyses, there were no significant differences in total fluid intake between PPD and non-PPD groups on POD 0 and POD 1--5 (Table [5](#Tab5){ref-type="table"}). In univariate analysis, there was no significant difference in total fluid output between groups over POD 1--5. Cumulative urine output in PPD patients was significantly less over POD 1--5 in univariate and multivariable analysis (effect = − 61.5, 95% CI \[− 110.3, − 12.7\], *p* = 0.015). Use of PPD was associated with significantly higher total fluid output over POD 1--5 in multivariable analysis (effect = 48.8, 95% CI \[2.2, 95.4\], p = 0.043). PPDs produced a mean output of 107 (st dev 82) mL/kg over POD 1--5 (Table [5](#Tab5){ref-type="table"}).

Diuretic Administration {#Sec12}
-----------------------

In univariate and multivariable analysis, PPD patients received significantly less furosemide than non-PPD patients over POD 1--5 (Table [5](#Tab5){ref-type="table"}). In multivariable analysis, the presence of a PPD accounted for 3.41 mg/kg less over POD 1--5 (95% CI \[1.69, 5.14\], *p* \< 0.001). Over POD 1--5, one PPD patient received chlorothiazide and furosemide but the remaining PPD patients received no diuretics other than furosemide, while 15 non-PPD patients received chlorothiazide in addition to furosemide.

Discussion {#Sec13}
==========

In a cohort of neonates and young infants \< 60 days old who were non-randomly selected for greater preoperative and surgical risk, we demonstrate that empiric passive peritoneal drainage is associated with increased total fluid output over the first five postoperative days even in the setting of reduced exposure to diuretics and similar fluid input. The thirty-four patients who received PPDs tended to be higher acuity, as evidenced by significant differences in STAT categories, age at surgery, bypass time, and presence of delayed chest closure. We were unable to demonstrate benefit in endpoints such as duration of mechanical ventilation or hospital length of stay in this cohort of patients.

Even after multivariable adjustment for recognized possible confounders, maximum daily vasoactive-inotropic scores were higher in the PPD patients. It is possible that our multivariable model does not identify all confounders that make the PPD cohort higher risk and contribute to a higher maximum daily VIS. Notably, high VIS is associated with prolonged time to net negative fluid status in infants after cardiopulmonary bypass \[[@CR12]\]. Our data demonstrates no significant difference in number of postoperative days to net negative despite the fact that PPD patients have significantly higher VIS.

Patients with PPD placement also had statistically higher incidences of KDIGO Stage 1 and Stage 2 acute kidney injury in univariate analysis, with a rate of 24% that is consistent with prior literature \[[@CR13], [@CR14]\]. Multivariable adjustment demonstrated no significant difference between the two groups for the incidence of KDIGO Stage 1 AKI, but the difference still trends toward significance for the incidence of KDIGO Stage 2. We cannot entirely exclude the possibility that the presence of a PPD somehow drives the higher VIS scores and rate of stage 2 AKI in these patients.

Recent work has demonstrated that fluid overload in neonatal patients after congenital heart surgery is associated with increased mortality and hospital length of stay independent of AKI, highlighting the importance of fluid management in these patients \[[@CR1]\]. Kwiatkowski, et al., demonstrated shorter time to net negative fluid balance and improved VIS in a cohort of patients with peritoneal drains, 60% of whom received dialysis at some point. This work also showed enhanced interleukin 6 (IL-6) clearance and reduced duration of mechanical ventilation \[[@CR4]\]. Other work has demonstrated that fluid removed via PPD or peritoneal dialysis contains pro-inflammatory IL-6 and IL-8 \[[@CR15]\]. Work in an ischemic AKI mouse model has demonstrated that peritoneal dialysis clears IL-6 and reduces lung inflammation \[[@CR16]\].

Our retrospective work examines the use of peritoneal drains with only passive drainage and does not demonstrate clear improvement in endpoints identified by Kwiatkowski, et al. \[[@CR4]\]. It is possible that this is because PPD is not as effective at removal of inflammatory cytokines as dialysis. Relevant work by Sasser, et al., found that, in consecutive eras, chest tube and urine output were similar between PPD patients and peritoneal dialysis patients but that the dialysis patients had lower IL-6 and IL-8 concentrations at 24 postoperative hours \[[@CR6]\].

Passive peritoneal drainage may be advantageous over peritoneal dialysis given its simplicity and that it may carry less risk of peritonitis. Saini, et al., demonstrated more rapid achievement of negative fluid balance in patients receiving a PPD after atrioventricular septal defect repairs \[[@CR8]\]. In 22 patients undergoing the Norwood operation, those randomized to PPD had similar clinical outcomes to those without PPD, including hospital length of stay, time to lactate below 2 mmol levels, time to extubation, and VIS \[[@CR9]\]. Our broader patient cohort does not demonstrate significant difference between PPD and non-PPD groups in end-outcomes.

Kwiatkowski et al. showed a decrease in ventilator time for patients with a peritoneal catheter, whether used for dialysis or passive drainage \[[@CR4]\]. Our work found no significant difference in the number of postoperative ventilator hours for our PPD patients. Our practice is to remove the PPD prior to extubation in order to reduce the risk of omental herniation. It is possible that some patients remained on the ventilator longer while awaiting the removal of their PPD, which would explain our different finding. However, this seems unlikely, as our care teams favor removal of the PPD earlier than otherwise desired to facilitate extubation if the patient is ready.

In PPD patients, we typically hold, or give small doses of, diuretic until urine output exceeds PD drain output. This may account for the decreased diuretics given to PPD patients in our study. Although diuretic use is a necessary tool in the armamentarium of congenital heart surgery, it is not without some risks and side effects. Loop diuretic treatment is associated with fluid and electrolyte imbalances including hyponatremia, hypokalemia, and hypochloremic metabolic alkalosis, which can depress respiratory drive and delay ventilator weaning. Use of furosemide in preterm infants is also associated with nephrocalcinosis, which itself may lead to glomerular and tubular dysfunction \[[@CR17]\].

In summary, we demonstrate that PPD placement enables greater total fluid output in the setting of less diuretic administration. Subjectively, prophylactic PPDs seem to provide an egress mechanism for third-spaced intracorporeal fluid during a time in which it is not otherwise mobilized due to factors including AKI, ongoing capillary leak, and sub-physiologic oncotic pressures. Although our current study does not demonstrate endpoint benefit, we hypothesize that PPD may favorably alter fluid management in a subset of high-risk neonate and young infants as they recover from CHS. Specifically, we suspect that PPD may provide more benefit to patients expected to have significant postoperative diastolic dysfunction as opposed to those with complex operations and high risk of AKI but without expected significant diastolic dysfunction. Further studies should evaluate, in randomized fashion, the use of prophylactic passive peritoneal drainage for fluid management after CHS to determine which, if any, patients are most likely to benefit from this approach.

Study Limitations {#Sec14}
-----------------

Patient cohorts were broad and divergent in this modest-sized retrospective study, and it is likely that our modeling does not account for all confounding preoperative and postoperative factors that may be associated with end outcomes. Patients were not randomized or blinded, and there were not predetermined study protocols for the selection of PPD patients or for the fluid management of either patient group. There was no specific protocol for timing of peritoneal drain removal. PPD patients had higher VIS scores and a trend towards higher rates of stage 2 AKI, and this retrospective work cannot entirely exclude the possibility that PPD presence somehow drives these findings. Treatment bias is a consideration, as it is possible that the decision to administer fluid resuscitation or vasoactive support could be influenced by the presence of a PPD. Analysis of electrolyte supplementation, especially in the setting of reduced diuretic administration, was not achievable given limitations in the data, wide array of postoperative critical illness, and variation in primary nutrition used in our patient cohorts.

Conclusions {#Sec15}
-----------

PPD placement in a cohort of young infants undergoing CHS with higher surgical and preoperative risk enables improved total body postoperative fluid output even in the setting of reduced diuretic administration. In this comparison across broad and divergent groups of PPD and non-PPD patients, endpoint benefit was not demonstrated. PPD utilization in all infants after CHS is not necessary or advocated by this work, as it is likely that only certain groups of high-risk infants, if any, would benefit. Further evaluation and randomized controlled studies are warranted to determine which, if any, cohorts of high-risk patients would benefit from PPD.
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